Distribution patterns of 18F-labelled fluoromethylcholine in normal structures and tumors of the head: A PET/MRI evaluation

Clinical Nuclear Medicine

Volumn 37, Issue 8, 2012, Pages

  Mertens, Koen ^a   Ham, Hamphrey ^a   Deblaere, Karel ^a   Kalala, Jean Pierre Okito ^a   Van Den Broecke, Caroline ^a   Slaets, Dominique ^b   De Vos, Filip ^b   Goethals, Ingeborg ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

18F labelled fluoromethylcholine; brain tumors; head region; MRI; normal structures; PET

Indexed keywords

FLUOROMETHYLCHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUORINE; FLUOROMETHYLCHOLINE; GADOLINIUM;

ADULT; AGED; ARTICLE; BONE MARROW; BRAIN DAMAGE; CANCER GRADING; CHOROID PLEXUS; CLINICAL ARTICLE; DEMYELINATING DISEASE; EXTRAOCULAR MUSCLE; FEMALE; GLIOMA; HUMAN; HYPOPHYSIS; LACRIMAL GLAND; MALE; MASTICATORY MUSCLE; MENINGIOMA; NOSE CAVITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PAROTID GLAND; POSITRON EMISSION TOMOGRAPHY; STRUCTURE ANALYSIS; BRAIN; BRAIN TUMOR; HEAD; MIDDLE AGED; MUSCLE; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; BRAIN; BRAIN NEOPLASMS; CHOLINE; FEMALE; FLUORINE RADIOISOTOPES; GADOLINIUM; HEAD; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUSCLES; POSITRON-EMISSION TOMOGRAPHY;

EID: 84863868658     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31824c5dd0     Document Type: Article

References (21)

1. Metser U, Miller E, Lerman H, et al. Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence. Am J Roentgenol. 2007;189:1203-1210. (Pubitemid 350033018)
2. Mertens K, Slaets D, Lambert B, et al. PET with (18)F-labelled choline-based tracers for tumour imaging: a review of the literature. Eur J Nucl Med Mol Imaging. 2010;37:2188-2193.
3. Bhakoo KK, Williams SR, Florian CL, et al. Immortalization and transformation are associated with specific alterations in choline metabolism. Cancer Res. 1996;56:4630-4635. (Pubitemid 26338062)
4. Nakagami K, Uchida T, Ohwada S, et al. Increased choline kinase activity and elevated phosphocholine levels in human colon cancer. Jpn J Cancer Res. 1999;90:419-424. (Pubitemid 29213547)
5. Schillaci O, Calabria F, Tavolozza M, et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun. 2010;31:39-45.
6. Blusztajn JK. Choline, a vital amine. Science. 1998;281:794-795. (Pubitemid 28376032)
7. Slaets D, De Bruyne S, Dumolyn C, et al. Reduced dimethylaminoethanol in F-18 fluorofluoromethylcholine: an important step toward enhanced tumour visualization. Eur J Nucl Med Mol Imaging. 2010;37:2136-2145.
8. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res. 2001;61:110-117. (Pubitemid 32095708)
9. Hara T, Kondo T, Hara T, et al. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg. 2003;99:474-479. (Pubitemid 37040406)
10. Kwee SA, Ko JP, Jiang CS, et al. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology. 2007;244:557-565. (Pubitemid 47080889)
11. Allen DD, Smith QR. Characterization of the blood-brain barrier choline transporter using the in situ rat brain perfusion technique. J Neurochem. 2001;76:1032-1041. (Pubitemid 32167376)
12. Lam WW, Ng DC, Wong WY, et al. Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumours - early experience. Clin Neurol Neurosurg. 2011;113:156-161.
13. Kwee SA, Coel MN, Lim J, et al. Combined use of F-18 fluorocholine positron emission tomography and magnetic resonance spectroscopy for brain tumour evaluation. J Neuroimaging. 2004;14:285-289. (Pubitemid 38781403)
14. Spaeth N, Wyss MT, Weber B, et al. Uptake of 18F-fluorocholine, 18F-fluoroethyl-L-tyrosine, and 18F-FDG in acute cerebral radiation injury in the rat: implications for separation of radiation necrosis from tumour recurrence. J Nucl Med. 2004;45:1931-1938. (Pubitemid 47618453)
15. Shinoura N, Nishijima M, Hara T, et al. Brain tumours: detection with C-11 choline PET. Radiology. 1997;202:497-503. (Pubitemid 27051749)
16. Giovacchini G, Fallanca F, Landoni C, et al. C-11 choline versus F-18 fluorodeoxyglucose for imaging meningiomas: an initial experience. Clin Nucl Med. 2009;34:7-10.
17. Fallanca F, Giovacchini G, Picchio M, et al. Incidental detection by [11C]choline PET/CTof meningiomas in prostate cancer patients. Q J Nucl Med Mol Imaging. 2009;53:417-421.
18. Grosu AL, Weber WA, Astner ST, et al. 11C-methionine PET improves the target volume delineation of meningiomas treated with stereotactic fractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2006;66:339-344. (Pubitemid 44332720)
19. Astner ST, Dobrei-Ciuchendea M, Essler M, et al. Effect of 11C-methionine-positron emission tomography on gross tumour volume delineation in stereotactic radiotherapy of skull base meningiomas. Int J Radiat Oncol Biol Phys. 2008;72:1161-1167.
20. Milker-Zabel S, Zabel-du Bois A, Henze M, et al. Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET. Int J Radiat Oncol Biol Phys. 2006;65:222-227.
21. Gehler B, Paulsen F, Oksuz MO, et al. [68Ga]-DOTATOC-PET/CT for meningioma IMRT treatment planning. Radiat Oncol. 2009;4:56.